Mounjaro appetite suppression not working — what's actually going on

Is the dose the issue, or is it the timeline?

The most common reason people report that Mounjaro's appetite suppression isn't working is straightforward: they're still on 2.5mg, which exists to let your body adjust to the medicine rather than to deliver the full therapeutic effect. The graduated schedule (2.5mg for four weeks, then typically 5mg, and so on) exists primarily to reduce side effects. Appetite changes tend to become more noticeable as the dose increases, and for some people the effect only becomes clearly consistent at 7.5mg or above.

Before concluding the medicine isn't doing anything, it's worth checking where you are in the schedule. If you've recently started or recently stepped up, give the current dose the full four weeks before assessing it. Many people describe week two or three of a new dose as the point things shift. Our page on how long Mounjaro takes to work sets out a realistic week-by-week picture of what early treatment often looks like.

If you're uncertain whether your lack of appetite suppression is expected for your current dose and duration, that's precisely the sort of question the broader 'Mounjaro not working' topic covers in more depth.

Why hunger can still break through even when the medicine is active

Tirzepatide works on two gut-hormone pathways (GIP and GLP-1) to slow gastric emptying and reduce appetite signals reaching the brain. But hunger is not a single dial. Sleep deprivation, high cortisol from stress, the luteal phase of the menstrual cycle, and eating very fast can all restore hunger signals that the medicine would otherwise quiet. That is not the medicine failing; it is other physiological processes temporarily overriding it.

Food choices matter too. Ultra-processed foods, especially those engineered to be highly palatable, are designed to defeat satiety signals. Eating them quickly (before gastric emptying has slowed) can produce genuine hunger well before the next meal. Protein and fibre at each meal help tirzepatide's satiety mechanism work with your physiology rather than against it. The NHS guidance on tirzepatide on the NHS website notes that the medicine should be used alongside a reduced-calorie diet for this reason.

One checking habit that takes under a minute: before your next meal, pause and rate your hunger on a simple 1–10 scale. If you're sitting at 6 or above regularly despite being several weeks into a therapeutic dose, note the time, what you ate last, and how long ago. A brief log over two or three days often reveals a pattern (late-afternoon hunger spikes linked to a light lunch, for example) that is easier to address than a medicine issue.

For a closer look at when the appetite effect typically arrives, how long suppression takes on Mounjaro covers the timeline in detail.

When it's a genuine clinical question, not just a waiting game

There are circumstances where absent appetite suppression signals something worth discussing with a prescriber. If you've been at the same dose for more than four weeks, have no dose increase pending, and consistently feel no reduction in hunger at all, that warrants a conversation. The same applies if you've reached a higher dose and the effect has disappeared after working previously, sometimes called a plateau, though this can reflect several different things.

It's also worth considering whether the medicine is being absorbed properly. Oral contraceptives may have reduced absorption during the first four weeks on tirzepatide and after each dose increase, as noted in NHS England's guidance on weight management injections. Other medicines you take at a similar time could theoretically affect gastrointestinal motility. Injection technique and storage conditions also matter: a pen stored outside the recommended refrigerated temperature, even briefly, may be affected.

People who find the medicine genuinely isn't producing any effect after a fair trial at therapeutic doses are sometimes reassured that switching between GLP-1 approaches can help, but that decision belongs with a prescriber, not a forum. Our overview page on Mounjaro covers the treatment landscape, and what to do if Mounjaro isn't working for you goes into next steps in more detail.

Results in context: what the trial evidence actually says about appetite

It's worth grounding expectations. In SURMOUNT-1, the pivotal phase 3 trial involving thousands of adults with obesity, participants on the highest tirzepatide dose achieved average body-weight reductions of around 20–21% over 72 weeks, reductions that are fundamentally driven by eating less over time. That implies the appetite effect was real and sustained for most participants. But not every week of that trial was identical, and not every participant had a linear experience.

Average outcomes don't tell you where you'll land individually. Genetics, baseline weight, metabolic rate and behavioural factors all shape the response. A realistic view of average weight loss on Mounjaro may help recalibrate your timeline without abandoning a treatment that is working more subtly than expected. And if you're weighing up whether Mounjaro is the right fit at all, the weight loss treatment overview sets out the options available through a regulated UK prescription service.

If you'd like a prescriber to review your current treatment (whether you're an existing patient or considering starting) a free consultation through our treatment page is the place to begin. Check your eligibility there, and a GPhC-registered prescriber will review your details the same day.